AstraZeneca’s sales rose 9 percent to $ 26.6 billion, thanks to new drugs and strong demand for anti-virus products such as asthma.
This increase offset the decline in revenue generated by other products, in which the distribution to patients was slowed by the pandemic, especially in oncology, due to the postponement of treatments to give priority to those against coronavirus.
In 2020, a year marked by a coronavirus pandemic, the British group has developed a vaccine along Oxford University.
In December, AstraZeneca received emergency approval to begin distributing its Covid-19 vaccine in the UK, followed by India, Argentina, Mexico, Morocco and the European Medicines Agency.
Also, the group has started the third phase of testing for an antibody-based drug against Covid-19.
AstraZeneca is committed to provide 170 million doses of vaccine in 190 countries around the globe.